ImaginAb Appoints Martyn Coombs as New Chief Executive Officer
LOS ANGELES, March 22, 2017 - ImaginAb Inc. today announced the appointment of Martyn Coombs as Chief Executive Officer.
Joseph Limber, chairman of ImaginAb, said “At ImaginAb we have exciting science and technology. Martyn has a strong track record that is directly relevant to our business, particularly in commercializing and making step changes in the value of products. We believe that with his leadership, we can realize our potential.”
Mr. Coombs is a recognized industry leader in nuclear medicine and imaging. Most recently, as president of Jubilant DraxImage Inc., he led the company through a period of rapid organic growth, tripling revenue in four years. He built a strong team, and advanced the development pipeline towards approval, specifically for Ruby-Fill®, a key PET cardiology product.
Mr. Coombs has also held senior leadership roles at Amersham (now GE Healthcare) and Nihon Medi-Physics, where he was the number two executive. Previously, he served as CEO of Asterand plc, a public life sciences company, where in 2008 he was recognized by the Financial Times for having the top performing stock on the London Stock Exchange.
Mr. Coombs holds a degree in mathematics, and an MBA with distinction from Warwick Business School.
Mr. Coombs will be initially based in the UK and travelling extensively to grow and develop ImaginAb's business.
Anna Wu, Ph.D., ImaginAb founder and chief scientific advisor said, "We are delighted to have Martyn join the ImaginAb team. This will help us position ImaginAb to deliver much-needed CD8 imaging tools for direct assessment of immune responses in immuno-oncology."
Mr. Coombs said: "ImaginAb’s technology appears to be disruptive based on work the team has conducted in the clinic as well as with pharmaceutical companies developing new drugs. I'm excited to join the team, and we will aim to transform ImaginAb into a successful company positively impacting patient care. I can't wait to start."
ImaginAb, Inc. is redefining therapeutic management by harnessing the power of antibody technology for in vivo imaging. The company’s proprietary antibody fragment platform yields actionable molecular information to guide treatment decisions in cancer and immunology. ImaginAb also collaborates with select biopharmaceutical partners to design imaging agents as companion diagnostics for therapeutic antibodies. ImaginAb’s technology is positioned to deliver on the promise of precision medicine by improving patient outcomes and reducing the cost of healthcare.
ImaginAb engineers antibody fragments called minibodies that maintain the exquisite specificity of full-length antibodies while remaining inert in the body. Used with widely available PET scan technology, these novel minibodies illuminate high-value molecular targets, providing physicians with a whole-body picture of immune activity. ImaginAb is advancing a best-in-class imaging agent to improve prostate cancer management and patient outcomes. For more information about ImaginAb’s pipeline and technology, visit www.imaginab.com.